title: Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats.
abstract: Individuals with functional lower urinary tract disorders including interstitial cystitis (IC)/bladder pain syndrome (BPS) and overactive bladder (OAB) often report symptom (e.g., urinary frequency) worsening due to stress. One member of the transient receptor potential ion channel vanilloid family, TRPV4, has recently been implicated in urinary bladder dysfunction disorders including OAB and IC/BPS. These studies address the role of TRPV4 in stress-induced bladder dysfunction using an animal model of stress in male rats. To induce stress, rats were exposed to 7 days of repeated variate stress (RVS). Quantitative PCR data demonstrated significant (P ≤ 0.01) increases in TRPV4 transcript levels in urothelium but not detrusor smooth muscle. Western blot analyses of split urinary bladders (i.e., urothelium and detrusor) showed significant (P ≤ 0.01) increases in TRPV4 protein expression levels in urothelial tissues but not detrusor smooth muscle. We previously showed that RVS produces bladder dysfunction characterized by decreased bladder capacity and increased voiding frequency. The functional role of TRPV4 in RVS-induced bladder dysfunction was evaluated using continuous, open outlet intravesical infusion of saline in conjunction with administration of a TRPV4 agonist, GSK1016790A (3 μM), a TRPV4 antagonist, HC067047 (1 μM), or vehicle (0.1% DMSO in saline) in control and RVS-treated rats. Bladder capacity, void volume, and intercontraction interval significantly decreased following intravesical instillation of GSK1016790A in control rats and significantly (P ≤ 0.01) increased following administration of HC067047 in RVS-treated rats. These results demonstrate increased TRPV4 expression in the urothelium following RVS and that TRPV4 blockade ameliorates RVS-induced bladder dysfunction consistent with the role of TRPV4 as a promising target for bladder function disorders.
authors: Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, Vermont.
authors: Liana
authors: L
authors: Merrill
authors: Department of Neurological Sciences, University of Vermont College of Medicine, Burlington, Vermont margaret.vizzard@uvm.edu.
authors: Margaret A
authors: MA
authors: Vizzard
mesh_terms: D000283:Administration, Intravesical; D000818:Animals; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D007930:Leucine / Q000008:administration & dosage / Q000031:analogs & derivatives; D008297:Male; D009025:Morpholines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000008:administration & dosage; D050916:TRPV Cation Channels / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D001743:Urinary Bladder / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D014550:Urinary Incontinence, Stress / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D014563:Urodynamics / Q000187:drug effects; D064804:Urological Agents / Q000008:administration & dosage*
chemical_list: C573308:HC-067047; D009025:Morpholines; C530602:N-(1-((4-(2-(((2,4-dichlorophenyl)sulfonyl)amino)-3-hydroxypropanoyl)-1-piperazinyl)carbonyl)-3-methylbutyl)-1-benzothiophene-2-carboxamide; D011758:Pyrroles; D012333:RNA, Messenger; D013449:Sulfonamides; D050916:TRPV Cation Channels; C486577:Trpv4 protein, rat; D064804:Urological Agents; D007930:Leucine
keywords: Q-PCR; TRPV4; Western blotting; bladder; micturition; stress